The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design.

IF 3.2 2区医学 Q2 CLINICAL NEUROLOGY

Journal of Neuro-Oncology Pub Date : 2025-05-20 DOI:10.1007/s11060-025-05082-1

Matthew Abikenari, Amit Regev, Vratko Himic, John Choi, Sanjeeva Jeyaretna, Daniel M Fountain, Michael Lim

{"title":"The hormonal nexus in PIK3CA-mutated meningiomas: implications for targeted therapy and clinical trial design.","authors":"Matthew Abikenari, Amit Regev, Vratko Himic, John Choi, Sanjeeva Jeyaretna, Daniel M Fountain, Michael Lim","doi":"10.1007/s11060-025-05082-1","DOIUrl":null,"url":null,"abstract":"<p><p>The presence of hormonal receptors in meningiomas has been known for decades. More recently, evidence has shown increased prevalence of meningiomas in patients taking certain types of hormonal treatments, such as oral contraceptives, progestins or hormone replacement therapy. Epidemiological evidence suggests that patients undergoing hormonal therapy harbor higher mutational rates of the oncogene PIK3CA. Due to the relative paucity of literature describing the intersection of hormone therapy and mutated PIK3CA pathways in meningioma, we have conducted a narrative review on this topic. Similarly, the clinical trial landscape for hormonal therapies for meningioma currently focuses on somatostatin receptor-targeted therapies and peptide receptor radionucleotide therapy, and the PIK3CA-hormonal signaling axis has not been explicitly targeted. Given the role of PIK3CA mutations in promoting cancer progression in other hormone-sensitive tumors, such as breast and prostate cancer, exploring this axis could inform drug repurposing including hormonal therapy specifically for these tumors.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-025-05082-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The presence of hormonal receptors in meningiomas has been known for decades. More recently, evidence has shown increased prevalence of meningiomas in patients taking certain types of hormonal treatments, such as oral contraceptives, progestins or hormone replacement therapy. Epidemiological evidence suggests that patients undergoing hormonal therapy harbor higher mutational rates of the oncogene PIK3CA. Due to the relative paucity of literature describing the intersection of hormone therapy and mutated PIK3CA pathways in meningioma, we have conducted a narrative review on this topic. Similarly, the clinical trial landscape for hormonal therapies for meningioma currently focuses on somatostatin receptor-targeted therapies and peptide receptor radionucleotide therapy, and the PIK3CA-hormonal signaling axis has not been explicitly targeted. Given the role of PIK3CA mutations in promoting cancer progression in other hormone-sensitive tumors, such as breast and prostate cancer, exploring this axis could inform drug repurposing including hormonal therapy specifically for these tumors.

查看原文本刊更多论文

pik3ca突变脑膜瘤中的激素关系：对靶向治疗和临床试验设计的影响。

几十年前人们就知道脑膜瘤中存在激素受体。最近，有证据表明，接受某些激素治疗（如口服避孕药、黄体酮或激素替代疗法）的患者脑膜瘤发病率增加。流行病学证据表明，接受激素治疗的患者具有更高的致癌基因PIK3CA突变率。由于描述脑膜瘤中激素治疗与PIK3CA通路突变交叉的文献相对缺乏，我们对这一主题进行了叙述性回顾。同样，脑膜瘤激素治疗的临床试验目前主要集中在生长抑素受体靶向治疗和肽受体放射性核苷酸治疗上，pik3ca -激素信号轴尚未明确靶向。考虑到PIK3CA突变在其他激素敏感肿瘤（如乳腺癌和前列腺癌）中促进癌症进展的作用，探索这一轴可以为药物再利用提供信息，包括针对这些肿瘤的激素治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neuro-Oncology 医学-临床神经学

CiteScore

6.60

自引率

7.70%

发文量

277

审稿时长

3.3 months

期刊介绍： The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.